Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg as an Analgesic for Short-Term Treatment in Female Subjects Suffering From Moderate-to-Severe Pain and Burning Upon Urination Associated With Uncomplicated Urinary Tract Infections (uUTI)

Amneal Pharmaceuticals

Status and phase

Completed

Phase 3

Conditions

Uncomplicated Urinary Tract Infections

Treatments

Drug: Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg

Drug: Phenazopyridine Hydrochloride Tables, USP 200 mg

Study type

Interventional

Funder types

Industry

Identifiers

NCT01650051

AM-PHN-004

Details and patient eligibility

About

The primary objective is to evaluate the safety and efficacy of Phenazopyridine HCl Tablets, USP 200 mg as a short term analgesic treatment of pain upon urination associated with Uncomplicated Urinary Tract Infections (uUTI).

The secondary exploratory objective is to evaluate safety and efficacy of Phenazopyridine HCl Tablets, USP 200 mg as a short term analgesic treatment of burning upon urination associated with uUTI.

Full description

Subjects will make separate self-assessments for severity of pain and burning upon urination using the NRS and self-assessments of their discomfort using the GSAS at designated intervals for 24 hours. Subjects will rate the effectiveness of the study medication using the SASMS at a designated interval for 24 hours.

Enrollment

424 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Is willing and able to provide and understand written informed consent for the study.
Is a female 18 years of age or older.
Has a clinical diagnosis of uncomplicated urinary tract infection (uUTI).
Has a reported history indicating a diagnosis of cystitis or urethritis.
Has a positive urine dipstick test showing the presence of nitrate or leukocyte esterase.
Has moderate to severe pain (score of 4 to 10 inclusive on the NRS) and burning (score of 4-10, inclusive on the NRS) upon urination.
Is willing and able to understand and comply with the requirements of the study.
Each female subject of childbearing potential (excluding women who are surgically sterilized or postmenopausal for at least 2 years) must have a negative urine pregnancy test at Screening and must be willing to use an acceptable form of birth control during the study. For the purpose of this trial, the following are considered acceptable methods of birth control: oral contraceptives, contraceptive patches, contraceptive implant, vaginal contraceptive, double barrier methods (eg, condom and spermicide), contraceptive injection (Depo-provera®), intrauterine device (IUD), hormonal IUD (Mirena®), and abstinence with a documented second acceptable method of birth control should the subject become sexually active.

Exclusion criteria

Is pregnant or breastfeeding during the study.
Has a diagnosis of a urinary tract or kidney disorder that is not a uUTI. Has a diagnosis of pyelonephritis (kidney infections when lower uUTI spreads to the upper tract).
Has taken an analgesic within 1 day prior to Visit 1.
Has taken any systemic anti-infectives within 7 days prior to Visit 1.
Has a history of G-6-PD deficiency or hemolytic anemia.
Has a known history of anatomical genitourinary (GU) anomalies or GU surgery within 6 months prior to Visit 1.
Has a chronic infection of the urinary tract requiring an intravenous pyelogram (IVP), ultrasound, or cystoscopy.
Is unable to comprehend the language of the informed consent and the self-evaluation scales.
Has serious acute illness (e.g., pneumonia) or an untreated or unstable medical illness that would likely interfere with assessments of uUTI.
Has received an investigational medication as part of a drug trial within 3 months prior to Visit 1.
Is currently participating in any other clinical study.
Has a history of severe drug allergy or hypersensitivity, including to phenazopyridine HCl or to any component of the study medications.
Consumes excessive amounts of alcohol, abuses drugs, or has any condition that would compromise compliance with this protocol.
Previous participation in this study.
Any clinically significant condition or situation, that in the opinion of the Investigator would interfere with the study evaluations or optimal participation in the study.
Prior use of phenazopyridine product within 3 years of enrollment.
Is an employee or direct relative of the study site or Investigator.